Home Respiratory Rehabilitation in Advanced Lung Cancer Chemotherapy Per os

Study Overview
=================
Brief Summary
-----------------
The feasibility and impact of respiratory rehabilitation (RR) in patients with advanced or metastatic (EGF-R WT or mutated) non-small cell lung cancer treated with oral targeted therapy including Inhibitors of EGF-R tyrosine kinases (TKI) and ALK inhibitors. These patients will benefit, at the beginning of the chemotherapy whatever the treatment line, of a respiratory rehabilitation. The respiratory rehabilitation takes place at the patient's home with the HAD's cooperation 3 hours per week, divided into 2 or 3 sessions. There is associated educational, nutritional and psychological support for a total duration of 8 weeks.

Official Title
-----------------
Home Respiratory Rehabilitation in Patients With Lung Cancer Non-small Cell Advanced or Metastatic Treated With Oral Targeted Therapy

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Other: Respiratory rehabilitation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with advanced or metastatic lung cancer In the course of treatment by oral chemotherapy of oral targeted therapy (tyrosine kinase inhibitor) in 1st, 2nd, 3rd line or more at the time of their inclusion Diagnosis of CP retained after multidisciplinary discussion of patient records Exclusion Criteria: Any residual toxicity of a previous antineoplastic treatment, grade> 2. Cardio-respiratory contraindications to exercise re-training: Angina unstable Recent infarct Tight aortic stenosis Unsteady heart failure Pericarditis, endocarditis, myocarditis Evolutionary thromboembolic disease Ventricular aneurysm Intra ventricular thrombus Uncontrolled rhythm disorders Instability of the respiratory state defined by uncompensated respiratory acidosis Carcinological contraindications: Bone metastases at risk of fracture and / or algae despite optimal analgesic treatment, symptomatic central nervous system metastases Presence of anemia (Hb <8g / dl or <10g / dl if patient with previous cardiac history), thrombocytopenia (<100,000 platelets / mm3) Chimio toxicity (neurological, cardiac) according to the investigator's assessment Neuromuscular contraindications: Neuromuscular and / or osteo-articular disease making it impossible to re-train Severe cognitive impairment Patient under tutorship or curatorship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Interventional Model Description: Patients with advanced or metastatic non-small cell lung cancer treated with oral targeted therapy (tyrosine kinase (TKI) inhibitors of EGF-R and ALK inhibitors), regardless of the treatment line.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 8 weeks Respiratory rehabilitation<br> | Other: Respiratory rehabilitation<br>* It consists of a global care of the patient: therapeutic education, nutritional maintenance, psychological support and re-training to the effort at home after discharge or after follow up visit of targeted therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients completing the full Respiratory Rehabilitation (8 weeks) at home |  | At 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional Assessment of Cancer Therapy Lung standardized | measure the quality of life | Baseline and 8 weeks | 
| EORTC QLQ C-30 standardized version 3.0 | Measure the quality of life | Baseline and 8 weeks | 
| Functional capacity | Exercise capacity with the six minutes walk test | Baseline and 8 weeks | 
| Respiratory capacity | measured by the spirometry | Baseline and 8 weeks | 
| Nutritional Risk Screening score | Nutritional state assessment by albumine and pre albumine dosage | Baseline and 8 weeks | 
| Body Mass Index |  | Baseline and 8 weeks | 
| Overall and progression-free survival |  | at 6 months |